- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00709579
Physiopathological Study and Pharmacological Modulation of Cutaneous Atrophy's Markers Induced by Glucocorticoids
Methodology :Phase III study, single centre, double blind, versus excipient, randomised, controlateral design.
Selection of the patients :Number of subjects required 60 :
- 30 patients needing an oral corticotherapy
- 30 patients needing a topical corticotherapy
Study Overview
Detailed Description
Study conduct
Two steps for each patient:
the first step lasting 3 months : assessment of changes in mechanisms involved in ACIC with the RV3391A cream (M0 à M3). At the beginning of the corticotherapy, each patient will apply RV3391A on anterior side of a forearm and the placebo on the other side (randomised) for 3 months.
Clinical exam and objective measurements will be realised.
This step will allow us to describe and compare the evolution of cutaneous atrophy's markers produced by glucocorticoïds markers between M0 and M3:
- between topical and oral corticotherapy
- between RV3391A and the placebo.
- the second step, the cohort follow-up, leading off the end of the first step (M3 à M24) The period of the second step will depend on the progression of patient's disease and on the period of his medical follow-up. This period may lasting until the 24th month after the inclusion in the study.
The patients will not apply RV3391A and the placebo anymore. They will be followed-up in the CHU.Assessments of the cutaneous atrophy's markers produced by glucocorticoïds will be realised at M6, M12, M18 and M24 with non invasive methods (clinical scoring, imaging, extensometry) to exactly describe on a long-term period the evolution of the ACIC. The assessments on forearm having received the placebo will allow us to know natural history of skin atrophy induced by corticotherapy.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Toulouse, France, 31052
- Centre Hopitalier Universitaire de Toulouse
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients needing an oral corticotherapy:
- aged over 50 years
- first corticotherapy over 0.5 mg/kg/day
- expectable period with a corticotherapy over 10 mg/day more than 3 months
- having signed a written informed consent form
- registered with a social security or health insurance system
Patients needing a topical corticotherapy:
- aged over 50 years
- topical corticotherapy with a high or very high potency corticoid over 10 g/day
- expectable period with a topical corticotherapy more than 3 months
- having signed a written informed consent form
- registered with a social security or health insurance system
Exclusion Criteria:
- Oral or topical corticotherapy within the last 3 months
- Cutaneous inflammation on the anterior side of the forearm
- Medical history of psychosis induced by corticotherapy
- Medical history of allergy to RV3391A product its and excipients.
- Medical history of allergy to mineral cream Avene SPF50 excipients.
- Medical history of allergy to latex, surgical tape, chlorhexidine, lidocaine or xylocaine
- Clotting disorder or anticoagulant intake
- Healing disorder
- Women who are not post-menopausal women
- Substitutive estrogenotherapy for less than 6 months
- Impossibility to be registered in the Volunteers National Register
- Inability to comply with requirements of the clinical monitoring program,
- Inability to personally sign the informed consent form
- Is deprived of his freedom by an administrative or judicial decision; or who is under guardianship or protective custody
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: placebo
|
placebo
|
Active Comparator: RV3391A
|
A standardized quantity of each product will be applied on the evening on anterior side of forearm.
The side of application will be randomized.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
20 Mhz echography : Dermal Thickness
Time Frame: M0 versus M3
|
M0 versus M3
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
20 Mhz echography : Dermal Thickness
Time Frame: M0 versus M6, M12, M18, M24
|
M0 versus M6, M12, M18, M24
|
Optical Coherent Tomography : Epidermal Thickness
Time Frame: M0, M1, M3, M6, M12, M18, M24
|
M0, M1, M3, M6, M12, M18, M24
|
Frosch Score
Time Frame: M0, M1, M3, M6, M12, M18, M24
|
M0, M1, M3, M6, M12, M18, M24
|
Cutometry: assessment of the skin mechanical properties
Time Frame: M0, M1, M3, M6, M12, M18, M24
|
M0, M1, M3, M6, M12, M18, M24
|
Histology: study of skin layers and assessment of collagen and other proteins.
Time Frame: M0, M3
|
M0, M3
|
Immunohistology and molecular biology: assessment of CD44, HB-EGF and erbB1, cutaneous cytokines, filaggrin, corneodesmosin and involucrin.
Time Frame: M0, M3
|
M0, M3
|
Peeling with an adhesive tape: sample of superficial epidermis layers and assessment by biochemical and immunodetection methods of anti-desmoglein, anti-kallikrein 7 and anti-corneodesmosin antibodies
Time Frame: M0, M3,
|
M0, M3,
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Laurent Sailler, Professor, Centre Hospitalier Universitaire
- Study Director: Anne-Marie Schmitt, Doctor, Pierre Fabre Dermo Cosmetique
- Study Director: Carle Paul, Professor, Centre Hospitalier Universitaire
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MODULCORTICOATROPHIE
- 2007-A00675-48
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cortico Atrophy
-
BionovoUnknownVaginal Atrophy | Vulvar AtrophyUnited States
-
Sun Pharmaceutical Industries LimitedTerminated
-
United States Army Research Institute of Environmental...RecruitingMuscular Disorders, Atrophic | Muscle Atrophy | Disuse Atrophy | Atrophy, Disuse | Disuse Atrophy Muscle of ThighUnited States
-
Robert WestermannWithdrawnMuscle Atrophy | ACL Tear | Quadriceps Muscle Atrophy | Muscle Atrophy, ProximalUnited States
-
University of JazanCompletedQuadriceps Muscle AtrophySaudi Arabia
-
DLR German Aerospace CenterCompletedMuscle; Atrophy, GeneralGermany
-
Sunnybrook Health Sciences CentreInnovation Fund of the Alternative Funding Plan from the Academic Health...Recruiting
-
McMaster UniversityUnknownSarcopenia | Muscle Atrophy | Muscle Disuse AtrophyCanada
-
Petra LarmoTurun Gynekologikeskus Oy; Tekes - The Finnish Funding Agency for Technology...CompletedVaginal Atrophy | Vaginal Dryness | Vulvar Atrophy | Vulvar DrynessFinland
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States